Use of small-molecule inhibitory compound of PERK-dependent signaling pathway as a promising target-based therapy for colorectal cancer.

In conclusion, PERK inhibitor 42215 may provide an innovative treatment strategy against colorectal cancer (CRC) via the activation of the pro-apoptotic branch of the PERK-mediated UPR signaling pathway.
PMID: 31906838 [PubMed - as supplied by publisher]

Source: Current Cancer Drug Targets - January 4, 2020 Category: Cancer & Oncology Authors: Rozpędek W, Pytel D, Wawrzynkiewicz A, Siwecka N, Dziki A, Dziki Ł, Diehl JA, Majsterek I Tags: Curr Cancer Drug Targets Source Type: research